Lapatinib Etibo 250mg 30 Tablet

Get a Price/Quote

MOQ : 10 Pieces

Lapatinib Etibo 250mg 30 Tablet Specification

Dosage Form
Oral tablet

Packaging Type
Box

Life Span
Refer to expiry date on packaging

Brand Name
Etibo

Pacakaging (Quantity Per Box)
30 Tablets

Indication
Breast cancer, specifically HER2-positive

Origin of Medicine
India

Salt Composition
Lapatinib 250mg

Drug Type
Prescription Only; Antineoplastic Agent

Ingredients
Lapatinib

Physical Form
Tablet

Function
Anticancer agent, used in cancer therapy

Recommended For
Patients with HER2-positive breast cancer

Dosage
250mg per tablet

Dosage Guidelines
As directed by the physician

Suitable For
Adults

Quantity
30 Tablets

Storage Instructions
Store below 30C in a dry place

Prescription Required
Yes

Therapeutic Area
Oncology

Product Registration
Available in select international markets (Canada, Europe, UK, USA, Australia)

ATC Code
L01XE07

Side Effects
May include diarrhea, rash, nausea, fatigue (refer to official leaflet)

Appearance
Film-coated tablet

Regulatory Status
Approved for medical use

Administration Route
Oral

Lapatinib Etibo 250mg 30 Tablet About

Spotlight the acclaimed Lapatinib Etibo 250mg 30 Tablet, an elite offering in oncology therapeutics for those facing HER2-positive breast cancer. This gorgeous, film-coated tablet contains the eminent ingredient Lapatinib and is prescribed for adults by healthcare professionals in select international markets, including Canada, Europe, the UK, USA, and Australia. Etibo's lavish approval for medical use under ATC Code L01XE07 signifies its strong regulatory standing. Each box delivers 30 tablets, designed for efficacious oral administration, with reliable therapeutic benefit and consistent quality. Store below 30C in a dry place for optimal potency.

Exceptional Features and Application Versatility

Lapatinib Etibo 250mg 30 Tablet is renowned for its lavish efficacy and convenience. Special features include a film-coated tablet form ensuring easy oral administration and precise dosage. The application media is oral, making it suitable for various clinical settings. This product is ideal for adult patients with HER2-positive breast cancer and can be administered under professional supervision, supporting medical practices across renowned healthcare surfaces, from clinics to eminent hospitals.

International Export Market, Sample Availability, and Certifications

The main export markets for Lapatinib Etibo 250mg 30 Tablet estimate consistent demand in elite regions - Canada, Europe, the UK, USA, and Australia. Certified as approved for medical use, the product ensures quality assurance at the point of handover. Samples may be available for authorized institutions, assisting in the sale price evaluation and regulatory compliance process. Etibo is delivered with all necessary certifications, making it a trusted choice for professional healthcare networks globally.

FAQ's of Lapatinib Etibo 250mg 30 Tablet:

Q: How should Lapatinib Etibo 250mg tablets be administered?

A: Lapatinib Etibo 250mg tablets are administered orally, following the specific dosage guidelines provided by your physician. Always adhere to the prescribed schedule for best results.

Q: What are the main benefits of using Lapatinib Etibo in cancer therapy?

A: Lapatinib Etibo is an eminent anticancer agent utilized in the targeted treatment of HER2-positive breast cancer, offering patients a valuable therapeutic option under medical supervision.

Q: Where is Lapatinib Etibo 250mg available for purchase?

A: This product is registered and available in select international markets, including Canada, Europe, the UK, USA, and Australia, through authorized prescriptions.

Q: When should I consider the use of Lapatinib Etibo?

A: Lapatinib Etibo is recommended for adults diagnosed with HER2-positive breast cancer. The decision to initiate therapy should be based on a healthcare provider's evaluation and guidance.

Q: What process should I follow if I experience side effects with Etibo?

A: If you experience side effects such as diarrhea, rash, nausea, or fatigue, refer to the official information leaflet and contact your healthcare provider for prompt assistance and advice.